ArticleJournal of inflammation research2025
Dupilumab-Induced Generalized Lichen Planus: A Case Report.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lichen planus (LP) is a chronic inflammatory skin disease of unknown cause. Common subtypes include generalized LP, linear LP, annular LP, and hypertrophic LP. Current clinical evidence suggests that lichen planus is a T-cell-mediated autoimmune disorder. Therefore, an increasing number of clinicians are opting for biologics or immunomodulators to manage lichen planus, but the reported evidence on their efficacy and safety remains limited. Case Summary: This case report describes a 32-year-old female with pre-existing localized lichen planus (LP) who developed generalized LP after IL-4Rα inhibitor dupilumab therapy. Following three dupilumab injections, progressive dissemination of pruritic pink-to-flesh-coloured or light-brown papules to the trunk and limbs was observed. The lesions regressed upon dupilumab discontinuation and pharmacological intervention. Diagnosis was confirmed by dermoscopy and histopathology. Conclusion: A temporal correlation and Naranjo adverse drug reaction score of 8 indicated dupilumab as the trigger, likely via Th1/Th2 immune deviation. This first-documented paradoxical reaction underscores dupilumab's potential to trigger generalized LP through immune deviation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.